Tocilizumab
- Generic Name
- Tocilizumab
- Brand Names
- Actemra, RoActemra, Tyenne, Tofidence
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 375823-41-9
- Unique Ingredient Identifier
- I031V2H011
- Background
Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 January 2010 to treat a number of inflamm...
- Indication
Tocilizumab is indicated to treat moderate to severe rheumatoid arthritis, giant cell arteritis, systemic sclerosis-associated interstitial lung disease, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and cytokine release syndrome.
...
- Associated Conditions
- Coronavirus Disease 2019 (COVID‑19), Cytokine Release Syndrome caused by CAR-T Cell Therapy, Giant Cell Arteritis (GCA), Juvenile Chronic Polyarthritis, Moderate to Severe Rheumatoid Arthritis, Moderately to Severely Active Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Systemic Juvenile Idiopathic Arthritis (SJIA), Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD), Active systemic Juvenile idiopathic arthritis, Severe, active Rheumatoid arthritis
- Associated Therapies
- Monotherapy
A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2022-05-06
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 40
- Registration Number
- NCT05364424
- Locations
- 🇺🇸
Chao Family Comprehensive Cancer Center UCI, Orange, California, United States
🇺🇸Memorial Cancer Institute at Memorial West, Pembroke Pines, Florida, United States
🇺🇸The University of Chicago, Chicago, Illinois, United States
Low-Dose Dobutamine and Single-Dose Tocilizumab in Acute Myocardial Infarction With High Risk of Cardiogenic Shock
- Conditions
- Interventions
- First Posted Date
- 2022-04-28
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Rigshospitalet, Denmark
- Target Recruit Count
- 100
- Registration Number
- NCT05350592
- Locations
- 🇩🇰
Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
Pilot CAR-T Cells Therapy for Children/Young Adults With CD19+ R/R Leukemia/Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2022-04-18
- Last Posted Date
- 2024-08-28
- Target Recruit Count
- 10
- Registration Number
- NCT05333302
- Locations
- 🇧🇾
Belarussian Research Center for Pediatric Oncology, Hematology and Immunology, Minsk, Minsk Region, Belarus
Combination of Inhaled DNase, Baricitinib and Tocilizumab in Severe COVID-19
- First Posted Date
- 2022-03-15
- Last Posted Date
- 2022-03-15
- Lead Sponsor
- Democritus University of Thrace
- Target Recruit Count
- 150
- Registration Number
- NCT05279391
- Locations
- 🇬🇷
University Hospital of Alexandroupolis, Alexandroupolis, Evros, Greece
ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma
- Conditions
- Interventions
- First Posted Date
- 2022-02-10
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Nationwide Children's Hospital
- Target Recruit Count
- 38
- Registration Number
- NCT05233397
- Locations
- 🇺🇸
Duke Children's Hospital, Durham, North Carolina, United States
🇨🇦McGill University Health Center, Montreal, Quebec, Canada
🇺🇸Children's Hospital Colorado, Aurora, Colorado, United States
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2022-02-02
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 53
- Registration Number
- NCT05219513
- Locations
- 🇫🇷
CHRU Lille - Hôpital Claude Huriez; Service des Maladies du Sang, Lille, France
🇮🇹ASST PAPA GIOVANNI XXIII; Ematologia, Bergamo, Lombardia, Italy
🇮🇹Istituto Clinico Humanitas;U.O. Oncologia Medica Ed Ematologia, Rozzano, Lombardia, Italy
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies
- Conditions
- Interventions
- First Posted Date
- 2022-01-26
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 320
- Registration Number
- NCT05207670
- Locations
- 🇺🇸
Infirmary Cancer Care, Mobile, Alabama, United States
🇺🇸Alaska Oncology & Hematology, LLC, Anchorage, Alaska, United States
🇺🇸Mayo Clinic Arizona, Phoenix, Arizona, United States
The Efficacy and Safety of Tocilizumab for Severe RP-ILD Secondary to Systemic Diseases
- First Posted Date
- 2022-01-06
- Last Posted Date
- 2022-01-06
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 68
- Registration Number
- NCT05181397
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, China
A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2021-12-29
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 242
- Registration Number
- NCT05171647
- Locations
- 🇺🇸
Ironwood cancer and research center, Chandler, Arizona, United States
🇺🇸City of Hope Cancer Center; Division of Medical Oncology & Experimental Therapeutics, Duarte, California, United States
🇺🇸Kaiser Permanente - Irvine, Irvine, California, United States
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2021-12-27
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 121
- Registration Number
- NCT05169515
- Locations
- 🇺🇸
UCSF/Hematology, Blood & Marrow Transplant, And Cellular Therapy (HBC) Program, San Francisco, California, United States
🇮🇹Irccs Ospedale San Raffaele;U.O. Oculistica, Milano, Lombardia, Italy
🇪🇸Hospital General Universitario Gregorio Maranon, Madrid, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.